on behalf of NSAIDs Survey Study Group (Appendix) Aim: To assess the appropriateness of gastroprotection in nonsteroidal anti-inflammatory drug (NSAID) users by primary care physicians.
T he adoption of nonsteroidal anti-inflammatory drug (NSAID) therapy in clinical practice resulted in a substantial reduction of morbidity and mortality related to cardiovascular disease, and improved the quality of life of patients suffering from chronic pain.
1,2 Low-dose antiplatelet agents have been shown to be effective in the primary and secondary prevention of cardiovascular events in patients who are at increased risk, such as the elderly or those with comorbidities.
1,2 Full-dose NSAIDs are well known to be very effective as anti-inflammatory and analgesic agents, and they are widely used in primary care for patients with rheumatologic or neoplastic diseases. 3 Unfortunately, during NSAID therapy, several gastrointestinal side effects may occur, which vary from dyspeptic symptoms to serious complications, including bleeding or perforation. 4, 5 For this reason, several studies investigated the possible risk factors associated with the occurrence of NSAID-related relevant gastrointestinal side effects, and the possible gastroprotective strategies. 6, 7 Advanced age (>65 y), a personal history of peptic ulcer, concomitant treatment with either anticoagulants, corticosteroids, or other NSAIDs, and the presence of serious comorbidities have been identified as significant risk factors for gastrointestinal events during NSAID therapy. 8, 9 With regard to protective strategies, proton pump inhibitor (PPI) therapy at standard doses has been widely recognized as the most effective approach for the prevention of gastrointestinal side effects in NSAID users. [10] [11] [12] Despite official guidelines recommending the use of gastroprotective therapy in NSAID users who are at a high risk for developing gastrointestinal complications, [13] [14] [15] evidence allowing for a widespread implementation of this strategy in primary care is still missing. Indeed, observational studies generally found an underuse of gastroprotective therapy in clinical practice in different countries. [16] [17] [18] [19] [20] This has also been reported in Italy, 21 despite the PPI therapy being dispensed by the National Health Service without any financial charge to long-term NSAID users who are at an increased high risk of gastrointestinal complications. An overuse of gastroprotective therapy has also been shown in low-risk NSAID users. 21 An inappropriate use of gastroprotective therapy could be expected to generate important consequences, with its underuse leaving some NSAID users at risk for potentially serious complications, with overuse resulting in futile long-term therapies and thus a substantial waste of economic resources.
On the basis of these observations, we designed this study to assess the management of NSAID users in primary care, in relation to the appropriate use of gastroprotective therapies.
PATIENTS AND METHODS

Study Design
This was a cross-sectional observational study focusing on the primary care physicians' (PCPs) management of NSAID users. Overall, 58 physicians who attended the postgraduate school for PCPs in Rome, participated in this study. The participating physicians were required, during the period of practice at PCP tutors ambulatory, to complete an individual questionnaire for all consecutive patients Z18 years of age, who were visited by PCPs during a 1-week period. Specifically, a paper questionnaire was filled out to collect data regarding the demographic and clinical characteristics of patients, who reported a chronic (more than 3 times a week for >6 mo) use of NSAIDs, including selective cyclooxygenase-2 inhibitors and antiplatelets agents (<300 mg aspirin, ticlopidine, and clopidogrel). Simultaneous therapy of either steroids or anticoagulants, a personal history of documented peptic ulcer (with or without complications), and the presence of relevant comorbidities were also registered, and data on gastroprotection therapy, including the type and dose of drug used. According to recommendations reported in the International guidelines and by opinion leaders, 10,14,15 PCP indications were considered appropriate when a gastroprotective therapy was prescribed for high-risk patients and no gastroprotection was performed in those patients without any risk factors (Table 1 ). To avoid the Hawthorne effect 22 -that is, the physicians could have been influenced in their decision of prescribing a gastroprotective therapy by the awareness of participating in this survey-the questionnaire focused exclusively on those patients already receiving NSAID therapy at the study visit, whereas data of patients in whom NSAID therapy was started at the study visit were not considered. In addition, the study enrolled only those patients who were actually visited by the PCPs, to avoid filling in the questionnaire by simply extracting archived-and potentially incorrect or not updated-data.
All patients consented collection of their clinical data, which were anonymously managed.
Statistical Analysis
Mean values, frequency, and 95% confidence intervals (CI) were calculated. Statistical comparisons for nominal or categorical variables were performed using the w 2 test or odds ratio (OR), and ANOVA was used for the continuous variables. Variables associated either significantly or with a P value <0.1 with an appropriate use of gastroprotective therapies were included in the regression logistic model with backward stepwise methodology.
RESULTS
The survey was performed in the ambulatory of 58 PCPs (Male/Female=50/8; class age: 41 to 50=1; class age: 51 to 60=38; class age: 51 to 60=19; number of assisted patients: 500 to 1000=3; 1000 to 1500=55). Overall, 3,433 patients (Male/Female: 1467/1966; mean age: 57.7 y; range, 18 to 96 y) were visited during the study period, and 869 (25.3%) of them were receiving a chronic NSAID therapy (Table 2 ). At least 1 risk factor for gastrointestinal complications was present in 727 (83.7%; 95% CI=81.2-86.2) of these patients, including age of >65 years in 602 cases and a clinical risk factor in the remaining 125 patients <65 years of age. Overall, a gastroprotection therapy was currently performed in 593 (68.2%) NSAID users. When comparing the appropriateness of PCP prescription with the available recommendations, the gastroprotection strategy seemed to be appropriate (ie, therapy prescribed when indicated; therapy not prescribed when not indicated) only in 299 (34.4%; 95% CI=31.2-37.6) patients, and being inappropriate in all the remaining cases. In particular, inappropriateness was due to the lack of prescription of gastroprotection therapy (ie, underuse) when indicated in 184 (30.6%; 95% CI=26.9-34.2) patients of Z65 years of age, including 164 (29.4%; 95% As far as the type of gastroprotection is concerned, 579 (97.6%) patients were taking a PPI, whereas 14 (2.4%) received an H 2 -receptor antagonist, with no patient being treated with misoprostol. As shown in Table 4 , half dose of either PPI (omeprazole 10 mg, lansoprazole 15 mg, pantoprazole 20 mg; 218 patients) or ranitidine (150 mg; 6 patients) was prescribed in 224 (38.7%; 95% CI=34.7-42.6) patients, whereas 21 patients (3.6%; 95% CI=2.1-5.1) received a double dose (esomeprazole 40 mg). Consequently, a standard dose of PPI was prescribed to 348 (66.3%; 95% CI=62.5-70.2) patients.
DISCUSSION
Our study showed that NSAIDs are widely used in primary care for both cardiovascular prevention and pain treatment, being prescribed to 1 in every 4 patients during the study period. [1] [2] [3] We also confirmed the relatively high prevalence of risk factors for gastrointestinal complications, such as advanced age, personal history of peptic ulcers, concomitant therapy with steroids, anticoagulants, or other NSAIDs, being reported by >80% of NSAID users. However, when assessing the appropriateness of PCP management of gastroprotective therapy in NSAID users, a disappointing 66% rate of inappropriate (overuse/underuse) indication was found, suggesting that roughly only 1 out of every 3 NSAID users may be expected to leave PCP office with the appropriate management. Our results were not unexpected. Previous studies had already shown gastroprotective therapy to be frequently neglected in chronic NSAID users at an increased risk for gastrointestinal complications, with prescription rates ranging from 19% to 45%. [15] [16] [17] [18] [19] [20] However, the results of these studies were partially hampered by the method used to collect the data. In some studies, data were collected by PCPs who were aware of the study design, so that the Hawthorne effect could not be excluded. 22 In other studies, data were based on prescription databases that failed to take into account all the clinical characteristics of patients. This seems to be different from this study in which, to provide a better estimate regarding the real-life prescription PCP pattern, data were collected by physicians who were actually performing clinical practice at PCP ambulatory.
When looking at the specific subgroups of NSAID users, our series also showed that an underutilization of gastroprotective therapy was registered in >30% of patients at increased risk, including those with 2 or more risk factors for gastrointestinal complications. In particular, we computed that the underuse rate of gastroprotective therapy was 4-fold higher in NSAID users, who concomitantly received a therapy with either steroid or anticoagulant agents. Therefore, PCPs seemed to fail to recognize these adjunctive risk factors for gastrointestinal complications as a critical variable in the gastroprotection management. Moreover, the underutilization rate of a gastroprotective therapy was significantly higher in >72-year-old patients (OR: 1.67), despite its widely accepted that the risk of gastroduodenal bleeding is significantly associated with advancing age. In our study, only 2 (14.3%) of 14 patients treated with a dual antiplatelet therapy (lowdose aspirin and clopidogrel) received gastroprotection, although current evidence does not support an eventual association between PPI use and cardiovascular events among clopidogrel users. 2 However, such behavior of PCPs could be justified by both Food and Drug Administration and the European Medicinal Agency recommendations, which discourage such an approach. 2 On the other hand, an overuse of gastroprotective therapy was also shown by our analysis. We computed that an overtreatment occurred in >50% of NSAID users without any risk factor for gastrointestinal side effects. This overtreatment is likely to result in an unwarranted therapeutic cost, subtracting economic resources from other more useful aims, such as treating high-risk patients.
Standard dose PPI therapy has been proven to be more effective than either misoprostol or ranitidine in preventing ulcer development in NSAID users. 10, 11 In this study, we computed that <60% of patients under gastroprotective therapy received a standard dose of PPI. Indeed, as many as 37.8% of patients were treated with half dose of PPI, despite the lack of evidence of a similar efficacy between half and standard doses. When coupling this observation on drug dosage with the high rate of inappropriateness (ie, underuse) previously described, the overall quality of gastroprotection management by PCPs seems to be rather poor. It could be argued that PCPs are involved in the management of different disciplines, such as cardiology, rheumatology, and other digestive diseases, so that it would be unrealistic to expect from them the same level of appropriateness achieved by specialists for each medical field. However, such an assumption should never become a license for harming patients. When a huge discrepancy in the appropriateness of the indication is present between PCPs and specialists, the possibility of implementing educational programmes and audits to improve the overall quality of medical care should be considered. For instance, PCPs also showed a relatively higher level of inappropriateness of gastrointestinal endoscopy indication as compared with gastroenterologists, although a clear inappropriate rate has been reported even for specialists. 23, 24 Therefore, educational interventions are probably required to improve patient management.
There are limitations to the present analysis. The crosssectional design of our study prevented us from ascertaining the real rate of gastrointestinal complications in high-risk patients without gastroprotection. However, it is well known that the risk of such complications in the absence of appropriate gastroprotection is substantial. Secondly, we compared the PCP behavior with international recommendations on this topic, without being sure that PCPs had been previously informed about the existence of these guidelines. However, when considering the very high prevalence of NSAIDs use among the patients of PCPs, the clinical difference between the lack of knowledge of specific guidelines and the lack of application of already known guidelines would seem meaningless. Thirdly, the analysis was limited to an Italian population, so it cannot be automatically applied to other countries. However, the consistency among the data available in the literature would suggest that this problem is far from being confined to 1 or a few countries. [16] [17] [18] [19] [20] Finally, the observational nature of our study prevented us from indicating effective measures to reduce the rate of inappropriateness of gastroprotection management in NSAID users by PCPs. When considering, however, that the core of the problem seems to be purely cultural, no technical ability is required to correctly prescribe a therapy, to provide an adequate amount of information or to maintain a high level of feedback.
To conclude, we have deduced that to ensure the correct prescription of gastroprotective therapy for NSAID users, tools to support PCPs further are required.
